123 related articles for article (PubMed ID: 31838898)
1. Benzofuran and pyrrole derivatives as cannabinoid receptor modulators with
Wadea NE; Issac MM; Osman NA; Abadi AH
Future Med Chem; 2019 Dec; 11(24):3139-3159. PubMed ID: 31838898
[No Abstract] [Full Text] [Related]
2. Structure-activity relationships of thiazole and benzothiazole derivatives as selective cannabinoid CB2 agonists with in vivo anti-inflammatory properties.
Ghonim AE; Ligresti A; Rabbito A; Mahmoud AM; Di Marzo V; Osman NA; Abadi AH
Eur J Med Chem; 2019 Oct; 180():154-170. PubMed ID: 31302448
[TBL] [Abstract][Full Text] [Related]
3. Synthesis and structure-activity relationships of a series of pyrrole cannabinoid receptor agonists.
Tarzia G; Duranti A; Tontini A; Spadoni G; Mor M; Rivara S; Vincenzo Plazzi P; Kathuria S; Piomelli D
Bioorg Med Chem; 2003 Sep; 11(18):3965-73. PubMed ID: 12927857
[TBL] [Abstract][Full Text] [Related]
4. Discovery of novel Tetrahydrobenzo[b]thiophene and pyrrole based scaffolds as potent and selective CB2 receptor ligands: The structural elements controlling binding affinity, selectivity and functionality.
Osman NA; Ligresti A; Klein CD; Allarà M; Rabbito A; Di Marzo V; Abouzid KA; Abadi AH
Eur J Med Chem; 2016 Oct; 122():619-634. PubMed ID: 27448919
[TBL] [Abstract][Full Text] [Related]
5. 1-Alkyl-2-aryl-4-(1-naphthoyl)pyrroles: new high affinity ligands for the cannabinoid CB1 and CB2 receptors.
Huffman JW; Padgett LW; Isherwood ML; Wiley JL; Martin BR
Bioorg Med Chem Lett; 2006 Oct; 16(20):5432-5. PubMed ID: 16889960
[TBL] [Abstract][Full Text] [Related]
6. New pyridazinone-4-carboxamides as new cannabinoid receptor type-2 inverse agonists: Synthesis, pharmacological data and molecular docking.
Ragusa G; Gómez-Cañas M; Morales P; Rodríguez-Cueto C; Pazos MR; Asproni B; Cichero E; Fossa P; Pinna GA; Jagerovic N; Fernández-Ruiz J; Murineddu G
Eur J Med Chem; 2017 Feb; 127():398-412. PubMed ID: 28088085
[TBL] [Abstract][Full Text] [Related]
7. Tricyclic pyrazoles. Part 6. Benzofuro[3,2-c]pyrazole: a versatile architecture for CB2 selective ligands.
Pinna G; Loriga G; Lazzari P; Ruiu S; Falzoi M; Frau S; Pau A; Murineddu G; Asproni B; Pinna GA
Eur J Med Chem; 2014 Jul; 82():281-92. PubMed ID: 24922543
[TBL] [Abstract][Full Text] [Related]
8. 3-Carboxamido-5-aryl-isoxazoles as new CB2 agonists for the treatment of colitis.
Tourteau A; Andrzejak V; Body-Malapel M; Lemaire L; Lemoine A; Mansouri R; Djouina M; Renault N; El Bakali J; Desreumaux P; Muccioli GG; Lambert DM; Chavatte P; Rigo B; Leleu-Chavain N; Millet R
Bioorg Med Chem; 2013 Sep; 21(17):5383-94. PubMed ID: 23849204
[TBL] [Abstract][Full Text] [Related]
9. The discovery of a potent and selective pyrazolo-[2,3-e]-[1,2,4]-triazine cannabinoid type 2 receptor agonist.
Moir M; Lane S; Montgomery AP; Hibbs D; Connor M; Kassiou M
Eur J Med Chem; 2021 Jan; 210():113087. PubMed ID: 33321261
[TBL] [Abstract][Full Text] [Related]
10. Latest progress in the identification of novel synthetic ligands for the cannabinoid CB2 receptor.
Han S; Chen JJ; Chen JZ
Mini Rev Med Chem; 2014 May; 14(5):426-43. PubMed ID: 24766386
[TBL] [Abstract][Full Text] [Related]
11. Endocannabinoid System as a Promising Therapeutic Target in Inflammatory Bowel Disease - A Systematic Review.
Hryhorowicz S; Kaczmarek-Ryś M; Zielińska A; Scott RJ; Słomski R; Pławski A
Front Immunol; 2021; 12():790803. PubMed ID: 35003109
[TBL] [Abstract][Full Text] [Related]
12. Novel pyrrole based CB2 agonists: New insights on CB2 receptor role in regulating neurotransmitters' tone.
Di Micco S; Ciaglia T; Salviati E; Michela P; Kostrzewa M; Musella S; Schiano Moriello A; Di Sarno V; Smaldone G; Di Matteo F; Capolupo I; Infantino R; Bifulco G; Pepe G; Sommella EM; Kumar P; Basilicata MG; Allarà M; Sánchez-Fernández N; Aso E; Gomez-Monterrey IM; Campiglia P; Ostacolo C; Maione S; Ligresti A; Bertamino A
Eur J Med Chem; 2024 Apr; 269():116298. PubMed ID: 38493727
[TBL] [Abstract][Full Text] [Related]
13. Synthesis, in vitro and in vivo evaluation of 1,3,5-triazines as cannabinoid CB2 receptor agonists.
Yrjölä S; Sarparanta M; Airaksinen AJ; Hytti M; Kauppinen A; Pasonen-Seppänen S; Adinolfi B; Nieri P; Manera C; Keinänen O; Poso A; Nevalainen TJ; Parkkari T
Eur J Pharm Sci; 2015 Jan; 67():85-96. PubMed ID: 25447744
[TBL] [Abstract][Full Text] [Related]
14. Synthesis and pharmacological evaluation of new biphenylic derivatives as CB2 receptor ligands.
Bertini S; Chicca A; Arena C; Chicca S; Saccomanni G; Gertsch J; Manera C; Macchia M
Eur J Med Chem; 2016 Jun; 116():252-266. PubMed ID: 27078864
[TBL] [Abstract][Full Text] [Related]
15. Biological characterization of PM226, a chromenoisoxazole, as a selective CB2 receptor agonist with neuroprotective profile.
Gómez-Cañas M; Morales P; García-Toscano L; Navarrete C; Muñoz E; Jagerovic N; Fernández-Ruiz J; García-Arencibia M; Pazos MR
Pharmacol Res; 2016 Aug; 110():205-215. PubMed ID: 27013280
[TBL] [Abstract][Full Text] [Related]
16. Structure-kinetic relationship studies of cannabinoid CB
Soethoudt M; Hoorens MWH; Doelman W; Martella A; van der Stelt M; Heitman LH
Biochem Pharmacol; 2018 Jun; 152():129-142. PubMed ID: 29574067
[TBL] [Abstract][Full Text] [Related]
17. Synthetic cannabinoid receptor agonists: classification and nomenclature.
Potts AJ; Cano C; Thomas SHL; Hill SL
Clin Toxicol (Phila); 2020 Feb; 58(2):82-98. PubMed ID: 31524007
[No Abstract] [Full Text] [Related]
18. Novel Triazolopyrimidine-Derived Cannabinoid Receptor 2 Agonists as Potential Treatment for Inflammatory Kidney Diseases.
Nettekoven M; Adam JM; Bendels S; Bissantz C; Fingerle J; Grether U; Grüner S; Guba W; Kimbara A; Ottaviani G; Püllmann B; Rogers-Evans M; Röver S; Rothenhäusler B; Schmitt S; Schuler F; Schulz-Gasch T; Ullmer C
ChemMedChem; 2016 Jan; 11(2):179-89. PubMed ID: 26228928
[TBL] [Abstract][Full Text] [Related]
19. Design, Synthesis, and SAR Studies of Heteroarylpyrimidines and Heteroaryltriazines as CB
Qian HY; Wang ZL; Chen LL; Pan YL; Xie XY; Xie X; Chen JZ
ChemMedChem; 2018 Nov; 13(22):2455-2463. PubMed ID: 30246417
[TBL] [Abstract][Full Text] [Related]
20. The SAR development of substituted purine derivatives as selective CB2 agonists for the treatment of chronic pain.
Guidetti R; Astles PC; Sanderson AJ; Hollinshead SP; Johnson MP; Chambers MG
Bioorg Med Chem Lett; 2014 Dec; 24(24):5572-5575. PubMed ID: 25466177
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
